Suzhou Zelgen Biopharmaceuticals Co Ltd Total Liabilities
Suzhou Zelgen Biopharmaceuticals Co Ltd total liabilities. Based on the latest financial reports, Suzhou Zelgen Biopharmaceuticals Co Ltd (688266) has total liabilities worth CN¥1.86 Billion CNY (≈ $272.82 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Suzhou Zelgen Biopharmaceuticals Co Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Suzhou Zelgen Biopharmaceuticals Co Ltd (2016–2024)
Total liabilities of Suzhou Zelgen Biopharmaceuticals Co Ltd from 2016 to 2024. This chart illustrates how Suzhou Zelgen Biopharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data.
Suzhou Zelgen Biopharmaceuticals Co Ltd Competitors by Total Liabilities
The table below lists competitors of Suzhou Zelgen Biopharmaceuticals Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HARBOUR ENE.SP.ADR LS-50
F:PQQ2
|
Germany | €25.54 Billion |
|
Nordic Semiconductor ASA
OL:NOD
|
Norway | Nkr328.31 Million |
|
Helmerich and Payne Inc
NYSE:HP
|
USA | $3.71 Billion |
|
Pampa Energía S.A
F:9PAA
|
Germany | €3.23 Billion |
|
Korn Ferry
NYSE:KFY
|
USA | $1.94 Billion |
|
Strauss Group
TA:STRS
|
Israel | ILA5.19 Billion |
|
Jiangsu Phoenix Publishing & Media Corp Ltd
SHG:601928
|
China | CN¥11.19 Billion |
|
Shenzhen Yan Tian Port Holdings Co Ltd
SHE:000088
|
China | CN¥4.15 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Suzhou Zelgen Biopharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Suzhou Zelgen Biopharmaceuticals Co Ltd.
Liquidity & Leverage Metrics
Suzhou Zelgen Biopharmaceuticals Co Ltd Total Liabilities Ratios Explained
Suzhou Zelgen Biopharmaceuticals Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.62 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Suzhou Zelgen Biopharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Suzhou Zelgen Biopharmaceuticals Co Ltd (2016–2024)
The table below shows the annual total liabilities of Suzhou Zelgen Biopharmaceuticals Co Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.75 Billion ≈ $256.37 Million |
+41.02% |
| 2023-12-31 | CN¥1.24 Billion ≈ $181.80 Million |
+41.05% |
| 2022-12-31 | CN¥880.82 Million ≈ $128.89 Million |
+78.71% |
| 2021-12-31 | CN¥492.88 Million ≈ $72.12 Million |
+76.85% |
| 2020-12-31 | CN¥278.69 Million ≈ $40.78 Million |
+13.05% |
| 2019-12-31 | CN¥246.52 Million ≈ $36.07 Million |
+42.30% |
| 2018-12-31 | CN¥173.24 Million ≈ $25.35 Million |
+132.21% |
| 2017-12-31 | CN¥74.61 Million ≈ $10.92 Million |
+168.71% |
| 2016-12-31 | CN¥27.76 Million ≈ $4.06 Million |
-- |
About Suzhou Zelgen Biopharmaceuticals Co Ltd
Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate … Read more